UCB SA (OTCMKTS:UCBJY – Get Free Report) reached a new 52-week high on Monday . The company traded as high as $100.01 and last traded at $99.97, with a volume of 9355 shares traded. The stock had previously closed at $97.35.
UCB Price Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business has a 50 day simple moving average of $95.75 and a 200-day simple moving average of $88.05.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Stories
- Five stocks we like better than UCB
- 3 Small Caps With Big Return Potential
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- What is the NASDAQ Stock Exchange?
- 2 Drone Stocks Surging from Increased Media Attention
- NYSE Stocks Give Investors a Variety of Quality Options
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
